TRIAL DETAIL
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Terminated |
|||
Phase: |
2 |
Start Date 08/01/2011 |
Age of Trial (yrs) 13.3 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PDGFRa inhibitor |
|||
Strategy: |
Block PDGFRA |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
14244, CP15-1008, 15B-IE-JGDH, 2010-022560-12 |
|||
Sponsor: |
ImClone LLC |
|||
Patient Contact: |
ImClone: ClinicalTrials@Imclone.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
The purpose of this study is to evaluate the tumor response of stable disease (SD) or better at 12 weeks in patients with Gastrointestinal Stromal Tumors (GIST) harboring PDGFRα mutations and patients with GIST not harboring PDGFRα mutations. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Baltimore |
MD |
21215 |
USA |
||
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |
|
Mannheim |
68167 |
Germany |
|||
Tuebingen |
D-72076 |
Germany |
|||
Leiden |
2333 |
Netherlands |
|||
Warsaw |
02-781 |
Poland |
|||
Madrid |
28050 |
Spain |
|||
Los Angeles |
CA |
90095 |
USA |
||
Post Falls |
ID |
83854 |
USA |
||
Minneapolis |
MN |
55455 |
USA |
||
3181 S.W. Sam Jackson Park Rd. |
Portland |
OR |
97239 |
USA |
|
Leuven |
B-3000 |
Belgium |
|||
Edegem |
B-2650 |
Belgium |
|||
Berlin |
Germany |
||||
Milan |
20132 |
Italy |
|||
Madrid |
28041 |
Spain |
|||
Chicago |
IL |
USA |
|||
Chicago |
IL |
USA |
|||
Essen |
Germany |